Saturday, December 20, 2014

Feltl starts Joint Corp. at strong buy

Feltl starts Joint Corp. at strong buy

December 19, 2014 by · Leave a Comment 

Tweet Feltl has initiated coverage of Joint Corp. (NASDAQ:JYNT) with a “strong buy” rating and price target of $12.45. The stock closed at $6.40 on Thursday. “The Joint is poised to further disrupt the chiropractic industry,” writes analyst Brent Rystrom, adding that for the past few years, the company has been growing rapidly as it […]

Amarantus in second closing of Series E preferred

Amarantus in second closing of Series E preferred

December 19, 2014 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has entered into definitive agreements to raise an additional $2-million under its previously announced transaction to issue Series E preferred stock, bringing the total capital raised to $5-million. “In recent months, we have been working towards further strengthening our balance sheet, and I am very pleased to have the ability […]

Nuvo Research finishes Phase 2 WF10 study

Nuvo Research finishes Phase 2 WF10 study

December 18, 2014 by · Leave a Comment 

Tweet One hundred seventy-nine patients have completed Nuvo Research’s (TSX:NRI) 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The company expects to release the top-line results of the study in mid-February of 2015. In a statement, Dr. Henrich Guntermann, president, Europe & […]

Leerink ups OvaScience price target to $56

Leerink ups OvaScience price target to $56

December 18, 2014 by · Leave a Comment 

Tweet Leerink Partners has raised its price target for “outperform-rated” OvaScience (NASDAQ:OVAS) to $56 from $23 after a company investor event where management announced major achievements for all three products. The stock closed at $34.96 on Wednesday. “Our key takeaways include AUGMENT training cycles (150 vs. 40-to-60) and announced pricing ($15,000-to-$25,000 vs. $15,000) exceed expectations, […]

HCW starts GenSpera at buy

HCW starts GenSpera at buy

December 17, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of GenSpera (OTCQB:GNSZ) with a “buy” rating and $2 price target. The stock closed at 61 cents on Tuesday. GenSpera has developed a novel platform to transform a cytotoxin into a targeted prodrug chemotherapy, which “we believe could help the company become a meaningful player in the currently estimated […]

Stifel ups Auspex Pharma price target

Stifel ups Auspex Pharma price target

December 17, 2014 by · Leave a Comment 

Tweet Stifel has raised its price target for “buy-rated” Auspex Pharmaceuticals (NASDAQ:ASPX) to $61 from $40 after the company posted positive Phase 3 data with its SD-809 drug candidate for treating chorea, or involuntary movement associated with Huntington’s disease. Shares of Auspex closed at $25.09 on Tuesday. Analyst Stephen Willey writes that the data “surpassed […]

Merus names Barry Fishman as CEO

Merus names Barry Fishman as CEO

December 16, 2014 by · Leave a Comment 

Tweet The board of Merus Labs International (NASDAQ:MSLI; TSX:MSL) appointed Barry Fishman as CEO, effective immediately. He has been serving as interim CEO since Sept. 23, 2014. Mr. Fishman has over 25 years of experience in the pharmaceutical industry and is the former CEO of Teva Canada. He began his pharmaceutical career at Eli Lilly, […]

Knight to invest $35-million in two funds

Knight to invest $35-million in two funds

December 16, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) through one of its wholly owned subsidiaries, has agreed to invest $25-million into Domain Partners IX LP and $10-million in Sanderling Ventures VII LP. These commitments follow Knight’s earlier investments with Sectoral, Forbion and Teralys. The five funds have combined assets under management in healthcare of approximately $9-billion. Domain Fund, which […]

Medifocus receives two Canadian patents

Medifocus receives two Canadian patents

December 15, 2014 by · Leave a Comment 

Tweet Medifocus (OTCQX:MDFZF; TSX-V:MFS) has obtained two newly allowed Canadian patents covering its platform technology for the treatment of breast cancer. The titles of the patents are “Thermotherapy Method for Treatment and Prevention of Breast Cancer” and the “Method for Improved Safety in Externally Focused Microwave Thermotherapy for Treating Breast Cancer.” A major embodiment of […]

WB starts Intersect ENT at outperform

WB starts Intersect ENT at outperform

December 12, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Intersect ENT (NASDAQ:XENT) with an “outperform” rating and “aggressive” growth company profile. The stock closed at $19.28 on Thursdays. Intersect is a pure-play on the large population of patients with chronic sinusitis. Its key products, Propel and Propel mini, are bioabsorbable stents used to reduce inflammation in the […]

Next Page »

Email Newsletters with Constant Contact
Google+